Pharmaceuticals - Diversified
Glenmark Pharmaceuticals Ltd Announces Issue Of Equity Pursuant To Exercise Of Options
Glenmark Pharmaceuticals Ltd announced that the board of directors at its meeting held on August 02, 2012, have allotted 33,500 shares to the employees of the Company on exercise of options.
Synta Pharmaceuticals Corp. Announces $25.8 Million Registered Direct Offering Of Common Stock
Synta Pharmaceuticals Corp. announced that it has entered into common stock subscription agreements with members of its Board of Directors for the sale of 3,976,702 shares of its common stock in a registered direct offering at a price of $6.49 per share, for gross proceeds of approximately $25.8 million. The shares were offered directly to the purchasers without a placement agent, underwriter, broker or dealer. The sale and issuance of the shares is expected to close on or about July 27, 2012. The net proceeds from the offering will be used to fund Synta’s operations, including advancement of Synta’s lead drug candidate, ganetespib, other research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for other general corporate purposes.
XenoPort, Inc. Announces Pricing of Public Offering of Common Stock
XenoPort, Inc. announced the pricing of an underwritten offering of 6,153,846 shares of its common stock at a price to the public of $6.50 per share. XenoPort has granted to the underwriters a 30-day option to purchase up to an additional 923,076 shares of its common stock. All of the shares in the offering are being offered by XenoPort. The offering is expected to close on or about July 30, 2012. Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the offering. RBC Capital Markets, LLC is acting as co-manager for the offering. A registration statement relating to the shares described above was previously filed with, and has been declared effective by, the Securities and Exchange Commission (SEC).
XenoPort, Inc. Announces Proposed Public Offering of Common Stock
XenoPort, Inc. announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the proposed public offering are to be sold by XenoPort. Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the offering. RBC Capital Markets, LLC is acting as co-manager for the offering.
Zogenix, Inc. Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
Zogenix, Inc. announced that it has priced an underwritten public offering of 32,500,000 units. Each unit consists of one share of common stock and a warrant to purchase 0.45 of a share of common stock, at a price to the public of $2.00 per unit. Net proceeds, after underwriting discounts and commissions and estimated offering costs, will be approximately $60.7 million. Zogenix intends to use the net proceeds from the offering to repay all amounts outstanding under its amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, to fund the pre-approval and pre-commercialization activities of Zohydro ER, for the ongoing commercialization of Sumavel DosePro and for working capital and other general corporate purposes. Zogenix has granted the underwriters a 30-day option to purchase up to 4,875,000 additional units to cover over-allotments, if any. The offering is expected to close on or about July 27, 2012, subject to satisfaction of customary closing conditions. Each warrant will have an exercise price of $2.50 per share, will be exercisable one year after the date of issuance and will expire five years from the date of issuance. Stifel Nicolaus Weisel and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Leerink Swann LLC is acting as lead co-manager for the offering. Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. are acting as co-managers for the offering.
Zogenix, Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
Zogenix, Inc. announced that it intends to offer units in an underwritten public offering, with each unit consisting of one share of Zogenix's common stock and a warrant to purchase a certain number of shares of Zogenix's common stock. All of the units are being offered by Zogenix. Zogenix intends to use the net proceeds from the offering to repay all amounts outstanding under its amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, to fund the pre-approval and pre-commercialization activities of Zohydro ER, for the ongoing commercialization of Sumavel DosePro and for working capital and other general corporate purposes. Stifel Nicolaus Weisel and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
4SC AG Comments on Capital Increase
4SC AG announced that on June 28, 2012 the subscription period in connection with the cash capital increase from authorized capital with subscription rights at a subscription price of EUR 1.50 ended. Prior to the commencement of the subscription offer Kempen & Co N.V., acting as sole global co-ordinator in the transaction, placed 2,911,000 shares with institutional investors in selected countries, by way of a pre-placement, at a price of EUR 1.50 per share. As a result, gross proceeds amounting to EUR 10,779,766.50 have already been secured. Shares not subscribed will be offered to institutional investors in selected countries by way of a rump placement on June 29, 2012. The rump placement will start with immediate effect and books will close on June 29, 2012. The Company intends to raise proceeds of between EUR 10 million and EUR 15 million in total from the capital increase. A public offering of the new shares is not made. Under the capital increase, the Company's share capital of EUR 41,968,304 is set to be increased by way of a partial utilization of the authorized capital by up to EUR 10,492,076.00 to an amount of up to EUR 52,460,380.00 through the issue of up to 10,492,076 new no-par value bearer shares, each representing a pro rata amount of the share capital of EUR 1.00 and having full dividend rights starting from January 1, 2012. The new shares are expected to be admitted for trade on the Frankfurt Stock Exchange in the third quarter of 2012.
Wuhan Humanwell Healthcare (Group) Co.,Ltd. to Issue New Shares in Private Placement
Wuhan Humanwell Healthcare (Group) Co.,Ltd. announced that it will issue up to 60 million A shares of common stock with par value of RMB 1 per share to up to 10 investors, to raise up to RMB 1.025 billion through private placement.
4SC AG Announces Details of Capital Increase
4SC AG announced that it has resolved to increase its capital. The subscription price for the new shares was set at EUR 1.50 per share. The Company's share capital of EUR 41,968,304 is set to be increased by way of a partial utilisation of the authorised capital by up to EUR 10,492,076 to an amount of up to EUR 52,460,380 through the issue of up to 10,492,076 new no-par value bearer shares, each representing a pro rata amount of the share capital of EUR 1.00 and having full dividend rights starting from January 1, 2012. The new shares will be offered for subscription to shareholders by way of an indirect subscription right for a subscription ratio of 4:1 in the period from June 15, 2012 to June 28, 2012. Arrangements for the trade of subscription rights will not be made. As part of the transaction, prior to the commencement of the subscription offer, Kempen & Co N.V., acting as sole global co-ordinator in the transaction, placed a total of 2,911,000 new shares with institutional investors in selected countries, by way of a private placement at a pre-placement price of EUR 1.50 per share. Thus, the pre-placement by the Company is set to generate gross proceeds of EUR 4,366,500.00. In total, the Company intends to raise proceeds of between EUR 10 million and EUR 15 million from the capital increase, with one major shareholder having already expressed its intention to participate in the capital increase with an amount of up to EUR 5 million.
Markets
- Sectors
- U.S.
- Europe
- Asia
Sector Summary
| Energy |  +0.03% |
| Basic Materials | +0.22% |
| Industrials | +0.15% |
| Cyclical Goods & Services | +0.16% |
| Non-Cyclical Goods & Services | +0.24% |
| Financials | +0.03% |
| Healthcare | +0.13% |
| Technology | +0.11% |
| Telecoms | +0.13% |
| Utilities | +0.37% |
| DOW | 15,294.50 |  -12.67 |
-0.08% |
| S&P 500 | 1,650.51 | -4.84 |
-0.29% |
| NASDAQ | 3,459.42 | -3.88 |
-0.11% |
| TR US Index | 149.65 | -0.39 |
-0.26% |
Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
